Atomoxetine-induced mydriasis.
Alhatem
Fadi J
FJ
Decker
David H
DH
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D005260:Female; D006801:Humans; D015878:Mydriasis / Q000139:chemically induced*; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride